In our prospective monocentric study, we analyzed the plasma levels of 14 fibrosis-associated biomarkers in 125 patients with hereditary (ATTRv) or wild-type transthyretin (ATTRwt) amyloidosis and demonstrated their significant association with clinically measured plasma levels and cardiovascular outcome in ATTR amyloidosis (ATTR-CA). The gene discussed is TTR; the disease is amyloidosis.